GSK to acquire RAPT Therapeutics, adding long-acting anti-IgE for food allergies
GSK has agreed to buy RAPT Therapeutics for $58 per share (~$2.2 billion equity, ~$1.9 billion net) to gain ozureprubart, a long-acting anti-IgE antibody in phase IIb aimed at prophylactic protection against food allergies. The therapy could allow dosing every 12 weeks (vs current injections every 2–4 weeks), addressing a major unmet need and expanding GSK’s allergy portfolio. The deal is structured as a tender offer with closing expected in Q1 2026, and includes milestone/royalty arrangements linked to RAPT’s partner.